Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 1.3.1.9 - enoyl-[acyl-carrier-protein] reductase (NADH) and Organism(s) Escherichia coli and UniProt Accession P0AEK4

for references in articles please use BRENDA:EC1.3.1.9
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
IUBMB Comments
The enzyme catalyses an essential step in fatty acid biosynthesis, the reduction of the 2,3-double bond in enoyl-acyl-[acyl-carrier-protein] derivatives of the elongating fatty acid moiety. The enzyme from the bacterium Escherichia coli accepts substrates with carbon chain length from 4 to 18 . The FAS-I enzyme from the bacterium Mycobacterium tuberculosis prefers substrates with carbon chain length from 12 to 24 carbons.
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Escherichia coli
UNIPROT: P0AEK4
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
hide
The taxonomic range for the selected organisms is: Escherichia coli
The enzyme appears in selected viruses and cellular organisms
Synonyms
pfenr, enoyl-acyl carrier protein, enoyl acyl carrier protein reductase, mtinha, enoyl acp reductase, nadh-dependent enoyl-acp reductase, enoyl-reductase, fabi2, fabi1, nadh-dependent enoyl-acyl carrier protein reductase, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
enoyl ACP reductase
-
enoyl reductase
-
enoyl-ACP reductase
-
enoyl-acyl carrier protein reductase
-
enoyl-[acyl-carrier-protein] reductase
-
cold-shock induced protein 15
-
-
-
-
CSI15
-
-
-
-
enoyl ACP reductase
-
-
enoyl-ACP reductase
enoyl-acyl carrier protein reductase
-
-
enoyl-[acyl-carrier-protein] reductase
-
-
NADH-dependent enoyl-ACP reductase
-
-
-
-
NADH-enoyl acyl carrier protein reductase
-
-
-
-
NADH-specific enoyl-ACP reductase
-
-
-
-
reductase, enoyl-[acyl carrier protein]
-
-
-
-
VEG241
-
-
-
-
vegetative protein 241
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
redox reaction
-
-
-
-
oxidation
reduction
PATHWAY SOURCE
PATHWAYS
-
-, -, -, -, -, -, -, -, -, -, -, -, -, -, -, -
SYSTEMATIC NAME
IUBMB Comments
acyl-[acyl-carrier protein]:NAD+ oxidoreductase
The enzyme catalyses an essential step in fatty acid biosynthesis, the reduction of the 2,3-double bond in enoyl-acyl-[acyl-carrier-protein] derivatives of the elongating fatty acid moiety. The enzyme from the bacterium Escherichia coli accepts substrates with carbon chain length from 4 to 18 [3]. The FAS-I enzyme from the bacterium Mycobacterium tuberculosis prefers substrates with carbon chain length from 12 to 24 carbons.
CAS REGISTRY NUMBER
COMMENTARY hide
37251-08-4
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
show the reaction diagram
-
-
-
?
crotonyl-CoA + NADH + H+
butyryl-CoA + NAD+
show the reaction diagram
trans-2-dodecenoyl-CoA + NADH
dodecanoyl-CoA + NAD+
show the reaction diagram
-
-
-
?
trans-2-octenoyl-N-acetylcysteamine + NADH
octanoyl-N-acetylcysteamine + NAD+
show the reaction diagram
-
-
-
?
2-hexenoyl-[acyl-carrier protein] + NADH
hexanoyl-[acyl-carrier protein] + NAD+
show the reaction diagram
-
-
-
-
?
2-octenoyl-[acyl-carrier protein] + NADH
octanoyl-[acyl-carrier protein] + NAD+
show the reaction diagram
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
show the reaction diagram
-
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
show the reaction diagram
-
-
-
-
?
crotonyl-CoA + NAD+
butyryl-CoA + NADH + H+
show the reaction diagram
-
activity assay
-
-
?
crotonyl-CoA + NADH + H+
butyryl-CoA + NAD+
show the reaction diagram
crotonyl-[acyl-carrier protein] + NADH
butyryl-[acyl-carrier protein] + NAD+
show the reaction diagram
enoyl esters of acyl-carrier protein + NADH
?
show the reaction diagram
-
last reductive step in fatty acid biosynthesis
-
-
?
enoyl-ACP + NADH + H+
acyl-ACP + NAD+
show the reaction diagram
-
-
-
-
?
trans-2,3-dehydracyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
show the reaction diagram
-
-
-
-
?
trans-2-decenoyl-[acyl-carrier protein] + NADH
decanoyl-[acyl-carrier protein] + NAD+
show the reaction diagram
-
syn addition via 2Re, 3Si attack on double bond
-
-
?
trans-2-dodecenoyl-CoA + NADH
dodecanoyl-CoA + NAD+
show the reaction diagram
-
-
-
-
?
trans-2-dodecenoyl-[acyl-carrier protein] + NADH
dodecanoyl-ACP + NAD+
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
show the reaction diagram
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
show the reaction diagram
-
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
show the reaction diagram
-
-
-
-
?
enoyl esters of acyl-carrier protein + NADH
?
show the reaction diagram
-
last reductive step in fatty acid biosynthesis
-
-
?
enoyl-ACP + NADH + H+
acyl-ACP + NAD+
show the reaction diagram
-
-
-
-
?
trans-2,3-dehydracyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
show the reaction diagram
-
-
-
-
?
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
-
Mg2+ has marginal effects on activity level
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1-hydroxy-2,3,1-benzodiazaborinine-2(1H)-carbothioamide
-
2,4,4'-trichloro-2'-hydroxydiphenyl ether
trivial name triclosan
2-(2,4-dichlorophenoxy)-5-chlorophenol
triclosan, dissociation constant of the inhibitor from the enzyme-NAD+ product complex: 7.0 pM
2-(2-hydroxyphenoxy)phenol
-
2-(toluene-4-sulfonyl)-2H-benzo[d][1,2,3]diazaborinin-1-ol
-
2-methylsulfonyl-6-methylbenzodiazaborine
-
2-methylsulfonyl-benzodiazaborine
-
2-phenoxyphenol
PP, dissociation constant of the inhibitor from the enzyme-NAD+ product complex: 0.5 microM
2-[amino(hydroxy)methyl]-2,3,1-benzodiazaborinin-1(2H)-ol
-
3-formyl-2-phenoxy phenol
3-hydroxy-4-phenoxy benzoic acid
3-hydroxy-4-phenoxy benzyl alcohol
4-(2',4'-dichlorophenoxy)-3-hydroxybenzaldehyde
4-(2',4'-dichlorophenoxy)-3-hydroxybenzoic acid
4-(2',4'-dichlorophenoxy)-3-hydroxybenzyl alcohol
4-(2',4'-dichlorophenoxy)-3-hydroxybenzylchloride
4-(2',4'-dinitrophenoxy)-3-hydroxybenzaldehyde
4-(2',4'-dinitrophenoxy)-3-hydroxybenzoic acid
inhibitory activity with recombinant purified protein, IC50: higher than 0.100 mM
5,11-dimethyl-8H-[2,3,1]benzodiazaborinino[2',1':5,6][1,3,5,2,6]oxadiazadiborinino[2,3-a][2,3,1]benzodiazaborinin-8-one
-
5-chloro-2-phenoxyphenol
CPP, dissociation constant of the inhibitor from the enzyme-NAD+ product complex: 1.1 pM
5-ethyl-2(2-hydroxyphenoxy)phenol
-
5-fluoro-2-phenoxyphenol
FPP, dissociation constant of the inhibitor from the enzyme-NAD+ product complex: 1.5 nM
5-methyl-2(2-hydroxyphenoxy)phenol
-
5-propyl-2(2-hydroxyphenoxy)phenol
-
6-methyl-2(propane-1-sulfonyl)-2H-thieno[3,2-d][1,2,3]diazaborinin-1-ol
-
curcumin
i.e. (E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, an uncompetitive inhibition of FabI, shows antibacterial activity against Escherichia coli, sensitivity is decreased in FabI-overexpressing Escherichia coli
genistein
i.e. 4',5,7-trihydroxyisoflavone
imperatorin
i.e. 9-[(3-methyl-2-buten-1-yl)oxy]-7H-furo[3,2-g][1]benzopyran-7-one
luteolin
i.e. 3',4',5,7-tetrahydroxyflavone, uncompetitive inhibition of FabI, sensitivity is decreased in FabI-overexpressing Escherichia coli
polydatin
i.e. 3,4',5-trihydroxystilbene-3-beta-D-glucopyranoside
triclosan
[5-chloro-2-(2,4-dichlorophenoxy)phenol]
i.e. triclosan, concentration required for 50% inhibition approximates to 50% of the enzyme concentration, competitive with respect to NADH, uncompetitive with respect to NAD+, inhibition is reversible and promoted by NAD+
[oxydi(2,3,1-benzodiazaborinine-1,2-diyl)]bis[(pyridin-4-yl)methanone]
-
(2E)-3-(1,2,3,4,5,6-hexahydropyrido[2,3-b][1,5]diazocin-8-yl)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide
-
-
(2E)-N-(3-methoxy-2-propoxybenzyl)-N-methyl-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
(2E)-N-(3-methoxy-2-propoxybenzyl)-N-methyl-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(3-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(4-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-b][1,5]diazocin-8-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-[3-(2-morpholin-4-ylethyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
-
-
(2E)-N-[(5-fluoro-3-methyl-1-benzothiophen-2-yl)methyl]-N-methyl-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
(2E)-N-[(5-fluoro-3-methyl-1-benzothiophen-2-yl)methyl]-N-methyl-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
-
-
(E)-1-benzyl-2-methyl-3-[2-(pyridin-3-yl)vinyl]-4-pyridone
-
IC50: higher than 0.100 mM
1,3-bis(2,6-dichlorobenzyl)-2-methyl-4-pyridone
-
IC50: 0.0084 mM
1,3-dibenzyl-2-methyl-4-pyridone
-
IC50: 0.020 mM
1-(3-chlorobenzyl)-3-(2,6-dichlorobenzyl)-2-methylpyridin-4(1H)-one
-
-
1-(4-aminobenzyl)-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
-
IC50: 0.00029 mM
1-benzyl-2-butyl-3-(2,6-dichlorobenzyl)-4-pyridone
-
IC50: 0.0045 mM
1-benzyl-2-methyl-3-(2,4,6-trichlorobenzyl)-4-pyridone
-
IC50: 0.0015 mM
1-benzyl-2-methyl-3-phenyl-4-pyridone
-
IC50: 0.0029 mM
1-benzyl-2-methyl-3-vinyl-4-pyridone
-
IC50: higher than 0.100 mM
1-benzyl-2-methyl-3-[2-(pyridin-3-yl)ethyl]-4-pyridone
-
IC50: higher than 0.100 mM
1-benzyl-3-(2,4-dichlorobenzyl)-2-methyl-4-pyridone
-
IC50: 0.0020 mM
1-benzyl-3-(2,6-dichlorobenzyl)-2-ethyl-4-pyridone
-
IC50: 0.00078 mM
1-benzyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
-
IC50: 0.00030 mM
1-benzyl-3-(2,6-difluorobenzyl)-2-methyl-4-pyridone
-
IC50: 0.0027 mM
1-benzyl-3-(2,6-dimethylbenzyl)-2-methyl-4-pyridone
-
IC50: 0.0043 mM
1-benzyl-3-(2-chloro-6-fluorobenzyl)-2-methyl-4-pyridone
-
IC50: 0.00039 mM
1-benzyl-3-(2-chlorobenzyl)-2-methyl-4-pyridone
-
IC50: 0.0042 mM
1-benzyl-3-butyl-2-methyl-4-pyridone
-
IC50: 0.061 mM
1-butyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
-
IC50: 0.00031 mM
1-cyclohexylmethyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
-
IC50: 0.00022 mM
1-decyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
-
IC50: 0.00022 mM
2-(2-hydroxybenzyl)-phenol
-
uncompetitive inhibition
2-(2-hydroxyphenyl)-phenol
-
uncompetitive inhibition
2-phenoxyphenol
-
noncompetitive inhibition
3-(2,6-dichlorobenzyl)-1,2-dimethyl-4-pyridone
-
IC50: 0.011 mM
3-(2,6-dichlorobenzyl)-1-(4-nitrobenzyl)-2-methyl-4-pyridone
-
IC50: 0.0018 mM
3-(2,6-dichlorobenzyl)-1-(5-hydroxypentyl)-2-methyl-4-pyridone
-
IC50: 0.0018 mM
3-(2,6-dichlorobenzyl)-1-furfuryl-2-methyl-4-pyridone
-
IC50: 0.00047 mM
3-(2,6-dichlorobenzyl)-2-methyl-1-(2-methyl-2-[[3-(trifluoromethyl)benzyl]sulfanyl]propyl)pyridin-4(1H)-one
-
-
3-(2,6-dichlorobenzyl)-2-methyl-1-(thiophen-2-ylmethyl)pyridin-4(1H)-one
-
-
3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
-
IC50: 0.120 mM
3-cyclohexylmethyl-1-benzyl-2-methyl-4-pyridone
-
IC50: 0.00040 mM
4-(4-hydroxyphenyl)-phenol
-
uncompetitive inhibition
4-hydroxymercuribenzoate
-
-
4-[3-(2,6-dichlorobenzyl)-2-methyl-4-pyridon-1-yl]methylbenzamide
-
IC50: 0.0025 mM
4-[3-(2,6-dichlorobenzyl)-2-methyl-4-pyridon-1-yl]methylbenzoic acid
-
IC50: 0.022 mM
5-chloro-2-(2,4-dichloro-phenoxy)phenol
-
trivial name triclosan, slow, tight-binding inhibitor
5-chloro-2-phenoxyphenol
-
slow binding inhibitor
5-fluoro-2-phenoxyphenol
-
slow binding inhibitor
5-methyl-2-phenoxyphenol
-
slow binding inhibitor
5-[3-(2,6-dichlorobenzyl)-2-methyl-4-pyridon-1-yl]pentanoic acid
-
IC50: 0.110 mM
6-butyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
-
IC50: 0.00038 mM
6-cyclohexylmethyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
-
IC50: 0.00029 mM
6-methyl-2-(propane-1-sulfonyl)-4a,7a-dihydro-2H-thieno[3,2-d][1,2,3]diazaborinin-1-ol
-
diazaborine derviative 2b18, 90% loss of NADH-dependent activity, 50% loss of NADPH-dependent activity at 0.52 mM
acetoacetyl-CoA
-
about 20% inhibition at 0.2 mM
cerulenin
-
-
decanoyl-CoA
-
about 15% inhibition at 0.2 mM
diazaborine
-
-
iodoacetate
-
-
isoniazid
-
-
lauroyl-CoA
-
about 50% inhibition at 0.2 mM
methyl 4-[3-(2,6-dichlorobenzyl)-2-methyl-4-pyridon-1-yl]methylbenzoate
-
IC50: 0.00030 mM
myristoyl-CoA
-
about 80% inhibition at 0.2 mM
palmitic acid
-
-
palmitoyl-CoA
stearoyl-CoA
-
about 40% inhibition at 0.2 mM
triclosan
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
N-ethylmaleimide
-
stimulation
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
4
crotonyl-CoA
-
0.01 - 0.4
NADH
0.003 - 0.079
trans-2-dodecenoyl-CoA
2.5 - 4.6
crotonyl-CoA
0.02
crotonyl-[acyl-carrier protein]
-
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00278
crotonyl CoA
-
0.45 - 11.9
trans-2-dodecenoyl-CoA
5.3
crotonyl-CoA
-
at pH 7.5 and 30°C
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1.15
crotonyl-CoA
-
at pH 7.5 and 30°C
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00062
3-formyl-2-phenoxy phenol
-
0.001
4-(2',4'-dichlorophenoxy)-3-hydroxybenzaldehyde
-
0.0013
4-(2',4'-dichlorophenoxy)-3-hydroxybenzoic acid
-
0.00185
4-(2',4'-dichlorophenoxy)-3-hydroxybenzyl alcohol
-
0.00275
4-(2',4'-dichlorophenoxy)-3-hydroxybenzylchloride
-
0.015
curcumin
pH 7.5, 22°C
0.0071
luteolin
pH 7.5, 22°C
0.00099
triclosan
-
0.000016
(2E)-3-(1,2,3,4,5,6-hexahydropyrido[2,3-b][1,5]diazocin-8-yl)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide
-
-
0.000055
(2E)-N-(3-methoxy-2-propoxybenzyl)-N-methyl-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
0.00033
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
-
-
0.000136
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
-
-
0.0000018
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
0.000012
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
-
-
0.000014
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
-
-
0.000017
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
0.000029
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
-
-
0.000039
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(3-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
-
-
0.00003
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(4-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-b][1,5]diazocin-8-yl)prop-2-enamide
-
-
0.000025
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
-
-
0.0000024
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
0.000014
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
-
-
0.000009
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
-
-
0.0000004
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
0.0000007 - 0.000007
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-[3-(2-morpholin-4-ylethyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]prop-2-enamide
0.00084
(2E)-N-methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
-
-
0.000024
(2E)-N-[(5-fluoro-3-methyl-1-benzothiophen-2-yl)methyl]-N-methyl-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
-
-
0.000025
(2E)-N-[(5-fluoro-3-methyl-1-benzothiophen-2-yl)methyl]-N-methyl-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
-
-
0.9
decanoyl-CoA
-
at pH 7.5 and 30°C
0.00015
indole
-
-
0.0054
palmitic acid
-
at pH 7.5 and 30°C
0.02
palmitoyl-CoA
-
-
additional information
additional information
inhibition kinetics, overview
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0013 - 0.002
3-formyl-2-phenoxy phenol
0.1
3-hydroxy-4-phenoxy benzoic acid
0.1
3-hydroxy-4-phenoxy benzyl alcohol
0.00183 - 0.01434
4-(2',4'-dichlorophenoxy)-3-hydroxybenzaldehyde
0.00225 - 0.01916
4-(2',4'-dichlorophenoxy)-3-hydroxybenzoic acid
0.00383 - 0.04004
4-(2',4'-dichlorophenoxy)-3-hydroxybenzyl alcohol
0.0057 - 0.01845
4-(2',4'-dichlorophenoxy)-3-hydroxybenzylchloride
0.1
4-(2',4'-dinitrophenoxy)-3-hydroxybenzaldehyde
0.1
4-(2',4'-dinitrophenoxy)-3-hydroxybenzoic acid
Escherichia coli
inhibitory activity with recombinant purified protein, IC50: higher than 0.100 mM
0.00075 - 0.00201
triclosan
0.1
(E)-1-benzyl-2-methyl-3-[2-(pyridin-3-yl)vinyl]-4-pyridone
Escherichia coli
-
IC50: higher than 0.100 mM
0.0084
1,3-bis(2,6-dichlorobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.0084 mM
0.02
1,3-dibenzyl-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.020 mM
0.00034 - 0.0033
1-(3-chlorobenzyl)-3-(2,6-dichlorobenzyl)-2-methylpyridin-4(1H)-one
0.00029
1-(4-aminobenzyl)-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.00029 mM
0.0045
1-benzyl-2-butyl-3-(2,6-dichlorobenzyl)-4-pyridone
Escherichia coli
-
IC50: 0.0045 mM
0.0015
1-benzyl-2-methyl-3-(2,4,6-trichlorobenzyl)-4-pyridone
Escherichia coli
-
IC50: 0.0015 mM
0.0029
1-benzyl-2-methyl-3-phenyl-4-pyridone
Escherichia coli
-
IC50: 0.0029 mM
0.1
1-benzyl-2-methyl-3-vinyl-4-pyridone
Escherichia coli
-
IC50: higher than 0.100 mM
0.1
1-benzyl-2-methyl-3-[2-(pyridin-3-yl)ethyl]-4-pyridone
Escherichia coli
-
IC50: higher than 0.100 mM
0.002
1-benzyl-3-(2,4-dichlorobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.0020 mM
0.00078
1-benzyl-3-(2,6-dichlorobenzyl)-2-ethyl-4-pyridone
Escherichia coli
-
IC50: 0.00078 mM
0.0003
1-benzyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.00030 mM
0.0027
1-benzyl-3-(2,6-difluorobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.0027 mM
0.0043
1-benzyl-3-(2,6-dimethylbenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.0043 mM
0.00039
1-benzyl-3-(2-chloro-6-fluorobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.00039 mM
0.0042
1-benzyl-3-(2-chlorobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.0042 mM
0.061
1-benzyl-3-butyl-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.061 mM
0.00031
1-butyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.00031 mM
0.00022
1-cyclohexylmethyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.00022 mM
0.00022
1-decyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.00022 mM
0.011
3-(2,6-dichlorobenzyl)-1,2-dimethyl-4-pyridone
Escherichia coli
-
IC50: 0.011 mM
0.0018
3-(2,6-dichlorobenzyl)-1-(4-nitrobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.0018 mM
0.0018
3-(2,6-dichlorobenzyl)-1-(5-hydroxypentyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.0018 mM
0.00047
3-(2,6-dichlorobenzyl)-1-furfuryl-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.00047 mM
0.0018
3-(2,6-dichlorobenzyl)-2-methyl-1-(2-methyl-2-[[3-(trifluoromethyl)benzyl]sulfanyl]propyl)pyridin-4(1H)-one
Escherichia coli
-
wild type enzyme, in 0.1 M sodium N-(2-acetamido)-iminodiacetic acid (pH 6.5)
0.0004 - 0.038
3-(2,6-dichlorobenzyl)-2-methyl-1-(thiophen-2-ylmethyl)pyridin-4(1H)-one
0.12
3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.120 mM
0.0004
3-cyclohexylmethyl-1-benzyl-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.00040 mM
0.0025
4-[3-(2,6-dichlorobenzyl)-2-methyl-4-pyridon-1-yl]methylbenzamide
Escherichia coli
-
IC50: 0.0025 mM
0.022
4-[3-(2,6-dichlorobenzyl)-2-methyl-4-pyridon-1-yl]methylbenzoic acid
Escherichia coli
-
IC50: 0.022 mM
0.11
5-[3-(2,6-dichlorobenzyl)-2-methyl-4-pyridon-1-yl]pentanoic acid
Escherichia coli
-
IC50: 0.110 mM
0.00038
6-butyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.00038 mM
0.00029
6-cyclohexylmethyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
Escherichia coli
-
IC50: 0.00029 mM
0.0003
methyl 4-[3-(2,6-dichlorobenzyl)-2-methyl-4-pyridon-1-yl]methylbenzoate
Escherichia coli
-
IC50: 0.00030 mM
0.00051 - 0.0099
triclosan
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.2
-
activity assay
7.4
-
FabI-inhibitory activity assay
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
22
assay at room temperature
25
activity assay
20
-
FabI-inhibitory activity assay at room temperature
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
120100
native PAGE
28000
4 * 28000
33000
-
monomeric form, SDS-PAGE
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
tetramer
4 * 28000
tetramer
-
crystallization experiments
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
complexed with NAD+ and triclosan, hanging drop vapor diffusion method
hanging drop vapor diffusion method, using 100 mM citrate pH 7.0, 100 mM ammonium sulfate, 22% (w/v) PEG 3350
complexed with NAD+, hanging drop vapor diffusion method
-
crystals of FabI/NAD+ complex with (E)-N-methyl-N-(1-methyl-1H-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthydrin-3-yl)acrylamide diffract to 2.3 A
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
A197M
no effect on triclosan inhibition
F203L
G93V
mutation decreases affinity of triclosan
M159T
mutation decreases affinity of triclosan
Y156F
mutation decreases affinity of triclosan
A95V aureus
-
triclosan-resistant mutant
G93V coli
-
triclosan-resistant mutant
additional information
-
construction of tetracysteine-tagged enzyme variants carrying the tag at the N-terminus, C-terminus, or both N- and C-terminus. All the tetracysteine-tagged FabI enzymes have high enzyme activities while the enhanced green fluorescent protein-tagged FabI exhaustively loses the activity. The binding between 4',5'-bis(1,3,2-dithioarsolan-2-yl)fuorescein, i.e. FlAsH reagent and tetracysteine motif is stable against high pressure, high field strength, high temperature, and ultrasound. A capillary zone electrophoresis system equipped with a laser-induced fluorescence detector has a detection limit of 10-16 M for the labeled proteins
pH STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.5
-
relatively stable above
390500
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
55
-
5 min stable
60
-
5 min, inactivation
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
HisTrap column chromatography
recombinant FabI
usung a Ni-NTA agarose column
Ni-NTA agarose column chromatography
-
no separation from NADPH-specific enzyme
-
Talon metal affinity resin column chromatography, and Superdex 200 gel filtration
-
using a Ni-NTA agarose column
-
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expressed in Escherichia coli BL21(DE3) cells
gene fabI, overexpression in Escherichia coli strain M15
the enoyl-[acyl-carrier-protein] reductase gene of Escherichia coli is cloned into a vector coding for the 6 x His tag for expression in Escherichia coli BL21DE3 cells
expressed in Escherichia coli Top10 cells
-
fabI gene from Escherichia coli DH5alpha was cloned into pBAD/Myc-His B vector for expression of the protein in Escherichia coli TOP10 cells
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
medicine
antibacterial target
analysis
-
construction of tetracysteine-tagged enzyme variants carrying the tag at the N-terminus, C-terminus, or both N- and C-terminus. All the tetracysteine-tagged FabI enzymes have high enzyme activities while the enhanced green fluorescent protein-tagged FabI exhaustively loses the activity. The binding between 4',5'-bis(1,3,2-dithioarsolan-2-yl)fuorescein, i.e. FlAsH reagent and tetracysteine motif is stable against high pressure, high field strength, high temperature, and ultrasound. A capillary zone electrophoresis system equipped with a laser-induced fluorescence detector has a detection limit of 10-16 M for the labeled proteins
medicine
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Saito, K.; Kawaguchi, A.; Seyama, Y.; Yamakawa, T.; Okuda, S.
Steric course of reaction catalyzed by the enoyl acyl-carrier-protein reductase of Escherichia coli
Eur. J. Biochem.
116
581-586
1981
Escherichia coli
Manually annotated by BRENDA team
Weeks, G.; Wakil, S.J.
Studies on the mechanism of fatty acid synthesis. 18. Preparation and general properties of the enoyl acyl carrier protein reductases from Escherichia coli
J. Biol. Chem.
243
1180-1189
1968
Escherichia coli
Manually annotated by BRENDA team
Saito, K.; Kawaguchi, A.; Okuda, S.; Seyama, Y.; Yamakawa, T.
Incorporation of hydrogen atoms from deuterated water and stereospecifically deuterium-labeled nicotin amide nucleotides into fatty acids with the Escherichia coli fatty acid synthetase system
Biochim. Biophys. Acta
618
202-213
1980
Escherichia coli
Manually annotated by BRENDA team
Bergler, H.; Fuchsbichler, S.; Hoegenauer, G.; Turnowsky, F.
The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA
Eur. J. Biochem.
242
689-694
1996
Escherichia coli
Manually annotated by BRENDA team
Baldock, C.; Rafferty, J.B.; Stuitje, A.R.; Slabas, A.R.; Rice, D.W.
The x-ray structure of Escherichia coli enoyl reductase with bound NAD+ at 2.1 ANG resolution
J. Mol. Biol.
284
1529-1546
1998
Escherichia coli
Manually annotated by BRENDA team
Ward, W.H.J.; Holdgate, G.A.; Rowsell, S.; McLean, E.G.; Pauptit, R.A.; Clayton, E.; Nichols, W.W.; Colls, J.G.; Minshull, C.A.; Jude, D.A.; Mistry, A.; Timms, D.; Camble, R.; Hales, N.J.; Britton, C.J.; Taylor, I.W.F.
Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan
Biochemistry
38
12514-12525
1999
Escherichia coli (P0AEK4), Escherichia coli
Manually annotated by BRENDA team
Sivaraman, S.; Zwahlen, J.; Bell, A.F.; Hedstrom, L.; Tonge, P.J.
Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs
Biochemistry
42
4406-4413
2003
Escherichia coli (P0AEK4)
Manually annotated by BRENDA team
Protasevich, II; Brouillette, C.G.; Snow, M.E.; Dunham, S.; Rubin, J.R.; Gogliotti, R.; Siegel, K.
Role of inhibitor aliphatic chain in the thermodynamics of inhibitor binding to Escherichia coli enoyl-ACP reductase and the Phe203Leu mutant: a proposed mechanism for drug resistance
Biochemistry
43
13380-13389
2004
Escherichia coli (P0AEK4), Escherichia coli
Manually annotated by BRENDA team
Seefeld, M.A.; Miller, W.H.; Newlander, K.A.; Burgess, W.J.; DeWolf, W.E., Jr.; Elkins, P.A.; Head, M.S.; Jakas, D.R.; Janson, C.A.; Keller, P.M.; Manley, P.J.; Moore, T.D.; Payne, D.J.; Pearson, S.; Polizzi, B.J.; Qiu, X.; Rittenhouse, S.F.; Uzinskas, I.N.; Wallis, N.G.; Huffman, W.F.
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
J. Med. Chem.
46
1627-1635
2003
Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Staphylococcus aureus
Manually annotated by BRENDA team
Sivaraman, S.; Sullivan, T.J.; Johnson, F.; Novichenok, P.; Cui, G.; Simmerling, C.; Tonge, P.J.
Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues
J. Med. Chem.
47
509-518
2004
Escherichia coli
Manually annotated by BRENDA team
Chhibber, M.; Kumar, G.; Parasuraman, P.; Ramya, T.N.; Surolia, N.; Surolia, A.
Novel diphenyl ethers: design, docking studies, synthesis and inhibition of enoyl ACP reductase of Escherichia coli and Escherichia coli
Bioorg. Med. Chem.
14
8086-8098
2006
Plasmodium falciparum, Escherichia coli (P0AEK4), Escherichia coli
Manually annotated by BRENDA team
Kitagawa, H.; Kumura, K.; Takahata, S.; Iida, M.; Atsumi, K.
4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI
Bioorg. Med. Chem.
15
1106-1116
2007
Escherichia coli, Staphylococcus aureus
Manually annotated by BRENDA team
Rafi, S.B.; Cui, G.; Song, K.; Cheng, X.; Tonge, P.J.; Simmerling, C.
Insight through molecular mechanics Poisson-Boltzmann surface area calculations into the binding affinity of triclosan and three analogues for FabI, the E. coli enoyl reductase
J. Med. Chem.
49
4574-4580
2006
Escherichia coli (P0AEK4)
Manually annotated by BRENDA team
Takahata, S.; Iida, M.; Yoshida, T.; Kumura, K.; Kitagawa, H.; Hoshiko, S.
Discovery of 4-pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus
J. Antibiot.
60
123-128
2007
Escherichia coli, Staphylococcus aureus
Manually annotated by BRENDA team
Karioti, A.; Skaltsa, H.; Zhang, X.; Tonge, P.J.; Perozzo, R.; Kaiser, M.; Franzblau, S.G.; Tasdemir, D.
Inhibiting enoyl-ACP reductase (FabI) across pathogenic microorganisms by linear sesquiterpene lactones from Anthemis auriculata
Phytomedicine
15
1125-1129
2008
Escherichia coli, Mycobacterium tuberculosis, Mycobacterium tuberculosis H37Rv, Plasmodium falciparum
Manually annotated by BRENDA team
Sampson, P.B.; Picard, C.; Handerson, S.; McGrath, T.E.; Domagala, M.; Leeson, A.; Romanov, V.; Awrey, D.E.; Thambipillai, D.; Bardouniotis, E.; Kaplan, N.; Berman, J.M.; Pauls, H.W.
Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI)
Bioorg. Med. Chem. Lett.
19
5355-5358
2009
Escherichia coli, Staphylococcus aureus
Manually annotated by BRENDA team
Ramnauth, J.; Surman, M.D.; Sampson, P.B.; Forrest, B.; Wilson, J.; Freeman, E.; Manning, D.D.; Martin, F.; Toro, A.; Domagala, M.; Awrey, D.E.; Bardouniotis, E.; Kaplan, N.; Berman, J.; Pauls, H.W.
2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI
Bioorg. Med. Chem. Lett.
19
5359-5362
2009
Escherichia coli, Staphylococcus aureus
Manually annotated by BRENDA team
Massengo-Tiasse, R.P.; Cronan, J.E.
Diversity in enoyl-acyl carrier protein reductases
Cell. Mol. Life Sci.
66
1507-1517
2009
Escherichia coli, Mycobacterium tuberculosis
Manually annotated by BRENDA team
Yao, J.; Zhang, Q.; Min, J.; He, J.; Yu, Z.
Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers
Bioorg. Med. Chem. Lett.
20
56-59
2010
Escherichia coli (P0AEK4), Escherichia coli MG1655 (P0AEK4)
Manually annotated by BRENDA team
Yang, H.; He, J.; Hu, F.; Zheng, C.; Yu, Z.
Detection of Escherichia coli enoyl-ACP reductase using biarsenical-tetracysteine motif
Bioconjug. Chem.
21
1341-1348
2010
Escherichia coli
Manually annotated by BRENDA team
Jordan, C.A.; Sandoval, B.A.; Serobyan, M.V.; Gilling, D.H.; Groziak, M.P.; Xu, H.H.; Vey, J.L.
Crystallographic insights into the structure-activity relationships of diazaborine enoyl-ACP reductase inhibitors
Acta Crystallogr. Sect. F
71
1521-1530
2015
Escherichia coli (P0AEK4)
Manually annotated by BRENDA team
Vick, J.E.; Clomburg, J.M.; Blankschien, M.D.; Chou, A.; Kim, S.; Gonzalez, R.
Escherichia coli enoyl-acyl carrier protein reductase (FabI) supports efficient operation of a functional reversal of ?-oxidation cycle
Appl. Environ. Microbiol.
81
1406-1416
2015
Escherichia coli
Manually annotated by BRENDA team
Ghattas, M.A.; Mansour, R.A.; Atatreh, N.; Bryce, R.A.
Analysis of enoyl-acyl carrier protein reductase structure and interactions yields an efficient virtual screening approach and suggests a potential allosteric site
Chem. Biol. Drug Des.
87
131-142
2016
Escherichia coli, Plasmodium falciparum, Mycobacterium tuberculosis (P9WGR1), Mycobacterium tuberculosis H37Rv (P9WGR1)
Manually annotated by BRENDA team